Please enable Javascript
Localized Renal Cell Carcinoma
Advertisement
Perioperative, Adjuvant Nivolumab Versus Surgery With Surveillance: RFS in High-Risk RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
July 8, 2024
The standard of care for intermediate to high-risk RCC consists of partial or radical nephrectomy and surveillance.
Read More
KIM-1 Biomarker Analysis in IMmotion010: Adjuvant Atezolizumab for RCC at High Recurrence Risk
Laurence Albiges, MD, PhD
Localized Renal Cell Carcinoma
|
June 10, 2024
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
View More
Preoperative Risk Calculator for Evaluating Nephron-Sparing Completion in Kidney Cancer
Katy Marshall
Localized Renal Cell Carcinoma
|
May 10, 2024
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Read More
Effects of Positive Surgical Margin in RCC After Adjuvant, Neoadjuvant Therapy
Katy Marshall
Localized Renal Cell Carcinoma
|
May 3, 2024
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Read More
Predictors of Renal Function Improvement After Partial Nephrectomy
Jonathan Afari, MD
Localized Renal Cell Carcinoma
|
April 24, 2024
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
View More
Predicting Renal Function Improvement After Partial Nephrectomy
Zachary Bessette
Localized Renal Cell Carcinoma
|
April 8, 2024
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
Read More
SABR Offers Acceptable Side Effect Profile, Efficacy for Primary RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
March 28, 2024
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
Read More
SABR Provides Novel Alternative to Surgical Resection for Primary RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
March 8, 2024
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
Read More
Transperitoneal Nephrectomy Offers Better Tumor Recurrence Than Retroperitoneal Procedure
Emily Menendez
Localized Renal Cell Carcinoma
|
February 15, 2024
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Read More
CheckMate 914 Part B: Nivolumab Monotherapy for Localized RCC After Nephrectomy
Viktor Grünwald, MD, PhD
ASCO GU Symposium 2024
|
January 30, 2024
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
View More
KEYNOTE-564: OS Results From Adjuvant Pembrolizumab for Clear Cell RCC
Zachary Bessette
ASCO GU Symposium 2024
|
January 27, 2024
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
Read More
CheckMate 914: Adjuvant Nivolumab Monotherapy for Patients With Localized RCC
Katy Marshall
ASCO GU Symposium 2024
|
January 30, 2024
The study's second phase analyzed data from patients with RCC scheduled to undergo radical or partial nephrectomy.
Read More
Targeted Gene Panel Testing Can Assist Patients With RCC, Germline Mutations
Emily Menendez
Localized Renal Cell Carcinoma
|
March 11, 2024
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Read More
Surgical Treatment for Renal Cancer Patients With Venous Tumor Thrombus
Katy Marshall
Localized Renal Cell Carcinoma
|
December 22, 2023
The retrospective study sought to determine if surgery would benefit patients and identify prognostic factors.
Read More
Partial Nephrectomy as an Alternative to Radical Nephrectomy for Patients With pT3aN0M0 RCC
Katy Marshall
SUO 2023
|
December 18, 2023
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
Read More
Kidney Cancer: Acting on Disparities and Intervening for Small Renal Masses
Zachary Bessette
SUO 2023
|
December 18, 2023
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Read More
Partial, Radical Nephrectomy After ICIs for Complex Locally Advanced RCC
Zachary Bessette
SUO 2023
|
November 22, 2023
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
Read More
Analyzing the Prognostic Potential of Biomarkers for ccRCC Treatment Stratification
Emily Menendez
2023 IKCS: North America
|
March 11, 2024
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Read More
Under-Utilization, Disparities in Genetic Testing for Patients With RCC
Katy Marshall
2023 IKCS: North America
|
March 11, 2024
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
Read More
Impact of Diabetes on Survival in Patients Undergoing Nephrectomy
Zachary Bessette
2023 IKCS: North America
|
November 10, 2023
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
Read More
Load More
Advertisement
Advertisement
Advertisement